For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 133,720 | |||
| General and administrative | 36,107 | |||
| Total operating expenses | 169,827 | |||
| Loss from operations | -169,827 | |||
| Interest income | 9,094 | |||
| Interest expense | 489 | |||
| Other expense, net | -85 | |||
| Total other income, net | 8,520 | |||
| Net loss | -161,307 | |||
| Basic EPS | -3.64 | |||
| Diluted EPS | -3.64 | |||
| Basic Average Shares | 44,259,999 | |||
| Diluted Average Shares | 44,259,999 | |||
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)